Canada - English - Health Canada

three rivers pharmaceuticals llc - amphotericin b - powder for suspension - 50mg - amphotericin b 50mg - polyenes

Canada - English - Health Canada

sterimax inc - amphotericin b - powder for solution - 50mg - amphotericin b 50mg - polyenes

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 12.5 ml - amb isome is indicated for the following: see dosage and administration for recommended doses by indication. amb isome is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin b deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.

United States - English - NLM (National Library of Medicine)

leadiant biosciences, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe), dimyristoylphosphatidylcholine, dl- (unii: u86zgc74v5) (dimyristoylphosphatidylcholine, dl- - unii:u86zgc74v5), dimyristoylphosphatidylglycerol, dl- (unii: bi71wt9p3r) (dimyristoylphosphatidylglycerol, dl- - unii:bi71wt9p3r) - amphotericin b 5 mg in 1 ml - abelcet ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin b therapy. this is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin b therapy (see description of clinical studies). description of clinical studies fungal infections data from 473 patients were pooled from three open-label studies in which abelcet ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin b, or who had preexisting nephrotoxicity. results of these studies demonstrated effectiveness of abelcet ® in the treatment of invasive fungal infections as a second line therapy. patients were defined by their individual physician as being refractory to or failing conventional amphotericin b therapy based on overall clinical judgement after receiving a minimu

United States - English - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 10 ml - amphotericin b for injection usp should be administered primarily to patients with progressive, potentially life-threatening fungal infections. this potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. amphotericin b for injection usp is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), north american blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera absidia , mucor and rhizopus , and infections due to related susceptible species of conidiobolus and basidiobolus , and sporotrichosis. amphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. this product is contraindicated in those patients who have shown hypersensitivity to amphote

United States - English - NLM (National Library of Medicine)

intermune, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - injection, lipid complex - 50 mg in 10 ml - amphotec is indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin b deoxycholate therapy has failed. amphotec should not be administered to patients who have documented hypersensitivity to any of its components, unless, in the opinion of the physician, the advantages of using amphotec outweigh the risks of hypersensitivity.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b liposome for injection is indicated for the following: - empirical therapy for presumed fungal infection in febrile, neutropenic patients. - treatment of cryptococcal meningitis in hiv infected patients (see description of clinical studies) . - treatment of patients with aspergillus species, candida species and/or cryptococcus species infections (see above for the treatment of cryptococcal meningitis) refractory to amphotericin b deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate. - treatment of visceral leishmaniasis. in immunocompromised patients with visceral leishmaniasis treated with amphotericin b liposome for injection, relapse rates were high following initial clearance of parasites (see description of clinical studies) . see dosage and administration for recommended doses by indication. amphotericin b liposome for injection is contraindicated in those patients who have demonstrated or have known hypersensiti

United States - English - NLM (National Library of Medicine)

eugia us llc - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b liposome for injection is indicated for the following: - empirical therapy for presumed fungal infection in febrile, neutropenic patients. - treatment of cryptococcal meningitis in hiv-infected patients (see description of clinical studies ). - treatment of patients with aspergillus species, candida species and/or cryptococcus species infections (see above for the treatment of cryptococcal meningitis) refractory to amphotericin b deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate. - treatment of visceral leishmaniasis. in immunocompromised patients with visceral leishmaniasis treated with amphotericin b liposome for injection, relapse rates were high following initial clearance of parasites (see description of clinical studies ). see dosage and administration   for recommended doses by indication. eleven clinical studies supporting the efficacy and safety of amphotericin b were conducted. this clinical program include